Carcinoid Tumor Clinical Trial
Official title:
Evaluation of Dual Energy CT for the Detection of Gastrointestinal Carcinoids
This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors. CT is an imaging technique that uses x-rays and a computer to create images of areas inside the body. Dual energy computed tomography is a technique used during routine CT scans to help obtain and process the image after the scan is complete. Doctors want to learn if dual energy computed tomography can help improve the detection of carcinoid tumors during routine CT scans.
PRIMARY OBJECTIVES: I. Evaluate prospectively the sensitivity and specificity of dual energy computed tomography (CT) in detecting primary gastrointestinal (GI) carcinoid. OUTLINE: Patients undergo one dual energy CT scan during scheduled CT scan. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05636618 -
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Active, not recruiting |
NCT03375320 -
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
|
Phase 3 | |
Completed |
NCT01435122 -
A Study of Axitinib in Advanced Carcinoid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT04039516 -
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
|
Phase 2 | |
Completed |
NCT00780663 -
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
|
Phase 2 | |
Completed |
NCT00804336 -
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
|
Phase 1 | |
Completed |
NCT03723499 -
Endoscopic Treatment of Bronchial Carcinoid Tumors
|
||
Recruiting |
NCT04017104 -
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
|
||
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Completed |
NCT00328497 -
A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
|
Phase 2 | |
Completed |
NCT02399215 -
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Terminated |
NCT03420521 -
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT05477576 -
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
|
Phase 3 | |
Not yet recruiting |
NCT02038738 -
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01024387 -
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00446082 -
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
|
Phase 1 | |
Active, not recruiting |
NCT05361668 -
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
|
Phase 2 | |
Completed |
NCT01466036 -
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
|
Phase 2 | |
Completed |
NCT01398306 -
Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.
|